{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:04:19Z","timestamp":1790690659448,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016615","name":"Curing Kids Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.bneo.2026.100247","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T22:27:07Z","timestamp":1778970427000},"page":"100247","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report"],"prefix":"10.1016","volume":"3","author":[{"given":"Eric S.","family":"Schafer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly L.","family":"Pacenta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9197-5684","authenticated-orcid":false,"given":"Yueh-Yun","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jemily","family":"Malvar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8362-549X","authenticated-orcid":false,"given":"Andrew","family":"Doan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1582-2168","authenticated-orcid":false,"given":"Reuven J.","family":"Schore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Rushing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Leong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Bujarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul S.","family":"Gaynon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8113-8180","authenticated-orcid":false,"given":"Seth E.","family":"Karol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio C.","family":"Barredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8025-6767","authenticated-orcid":false,"given":"Susan R.","family":"Rheingold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Van","family":"Huynh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan P.","family":"Gossai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3783-1820","authenticated-orcid":false,"given":"Bill H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamra","family":"Slone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-5836","authenticated-orcid":false,"given":"Melinda","family":"Pauly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S.","family":"Wayne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepa","family":"Bhojwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8293-4242","authenticated-orcid":false,"given":"Terzah M.","family":"Horton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bneo.2026.100247_bib1","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/s41572-024-00525-x","article-title":"Acute lymphoblastic leukaemia","volume":"10","author":"Pagliaro","year":"2024","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.bneo.2026.100247_bib2","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1038\/s41375-024-02395-4","article-title":"Determinants of survival after first relapse of acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"38","author":"Rheingold","year":"2024","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.bneo.2026.100247_bib3","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1080\/17474086.2016.1216311","article-title":"The role of proteasome inhibition in the treatment of malignant and non-malignant hematologic disorders","volume":"9","author":"Citrin","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"10.1016\/j.bneo.2026.100247_bib4","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0093-7754(01)90034-X","article-title":"Proteasome inhibition in cancer: development of PS-341","volume":"28","author":"Adams","year":"2001","journal-title":"Semin Oncol"},{"issue":"8","key":"10.1016\/j.bneo.2026.100247_bib5","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1182\/blood.V98.8.2301","article-title":"Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells","volume":"98","author":"Guzman","year":"2001","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.bneo.2026.100247_bib6","doi-asserted-by":"crossref","first-page":"16220","DOI":"10.1073\/pnas.252462599","article-title":"Preferential induction of apoptosis for primary human leukemic stem cells","volume":"99","author":"Guzman","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.bneo.2026.100247_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00280-005-0135-z","article-title":"Bortezomib interactions with chemotherapy agents in acute leukemia in vitro","volume":"58","author":"Horton","year":"2006","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"10.1016\/j.bneo.2026.100247_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3816\/CLM.2002.n.011","article-title":"Proteasome inhibitors in the treatment of B-cell malignancies","volume":"3","author":"Schenkein","year":"2002","journal-title":"Clin Lymphoma"},{"issue":"3","key":"10.1016\/j.bneo.2026.100247_bib9","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/j.1365-2141.2006.06170.x","article-title":"Proteasome inhibition as novel treatment strategy in leukaemia","volume":"134","author":"Vink","year":"2006","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100247_bib10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2174\/156800908783769300","article-title":"Ubiquitylation and cancer development","volume":"8","author":"Miasari","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"issue":"12","key":"10.1016\/j.bneo.2026.100247_bib11","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1038\/sj.leu.2403987","article-title":"Sensitivity of human multiple myelomas and myeloid leukemias to the proteasome inhibitor I","volume":"19","author":"Servida","year":"2005","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.bneo.2026.100247_bib12","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1200\/JCO.2005.11.030","article-title":"Proteasome inhibition as a novel therapeutic target in human cancer","volume":"23","author":"Rajkumar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bneo.2026.100247_bib13","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.abb.2015.12.012","article-title":"Mammalian proteasome subtypes: their diversity in structure and function","volume":"591","author":"Dahlmann","year":"2016","journal-title":"Arch Biochem Biophys"},{"issue":"1","key":"10.1016\/j.bneo.2026.100247_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/pbc.21214","article-title":"Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program","volume":"50","author":"Houghton","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"10.1016\/j.bneo.2026.100247_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29999","article-title":"Phase 1b study of carfilzomib with induction chemotherapy in pediatric relapsed\/refractory acute lymphoblastic leukemia","volume":"69","author":"Burke","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.bneo.2026.100247_bib16","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/bjh.15919","article-title":"Bortezomib reinduction chemotherapy in high-risk ALL in first relapse: a report from the Children's Oncology Group","volume":"186","author":"Horton","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100247_bib17","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1182\/blood-2012-04-418640","article-title":"Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study","volume":"120","author":"Messinger","year":"2012","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.bneo.2026.100247_bib18","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1200\/JCO.21.02678","article-title":"Children's Oncology Group Trial AALL1231: a phase III clinical trial testing bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma","volume":"40","author":"Teachey","year":"2022","journal-title":"J Clin Oncol"},{"issue":"5-6","key":"10.1016\/j.bneo.2026.100247_bib20","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.drudis.2010.01.008","article-title":"Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy","volume":"15","author":"Dick","year":"2010","journal-title":"Drug Discov Today"},{"issue":"5","key":"10.1016\/j.bneo.2026.100247_bib21","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"issue":"12","key":"10.1016\/j.bneo.2026.100247_bib22","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3324\/haematol.2013.092411","article-title":"Higher ratio immune versus constitutive proteasome level as novel indicator of sensitivity of pediatric acute leukemia cells to proteasome inhibitors","volume":"98","author":"Niewerth","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.bneo.2026.100247_bib23","first-page":"217","article-title":"Spotlight on ixazomib: potential in the treatment of multiple myeloma","volume":"10","author":"Muz","year":"2016","journal-title":"Drug Des Devel Ther"},{"issue":"2","key":"10.1016\/j.bneo.2026.100247_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.bneo.2026.100247_bib25","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/pbc.22414","article-title":"Toxicity assessment of molecularly targeted drugs incorporated into multiagent chemotherapy regimens for pediatric acute lymphocytic leukemia (ALL): review from an International Consensus Conference","volume":"54","author":"Horton","year":"2010","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.bneo.2026.100247_bib26","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"issue":"13","key":"10.1016\/j.bneo.2026.100247_bib27","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Kumar","year":"2014","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.bneo.2026.100247_bib28","doi-asserted-by":"crossref","first-page":"2316","DOI":"10.1038\/s41375-018-0094-0","article-title":"Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"issue":"16","key":"10.1016\/j.bneo.2026.100247_bib29","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1182\/blood.2019004043","article-title":"How I treat relapsed acute lymphoblastic leukemia in the pediatric population","volume":"136","author":"Hunger","year":"2020","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.bneo.2026.100247_bib30","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27224","volume":"65","author":"Trucco","year":"2018","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.bneo.2026.100247_bib31","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.14569","article-title":"A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114)","volume":"177","author":"Rheingold","year":"2017","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.bneo.2026.100247_bib32","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30609","article-title":"Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed\/refractory acute lymphoblastic leukemia and lymphoma: a Children's Oncology Group study (AINV18P1)","volume":"70","author":"Raetz","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"10.1016\/j.bneo.2026.100247_bib33","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1158\/1078-0432.CCR-19-1251","article-title":"Decitabine and vorinostat with chemotherapy in relapsed pediatric acute lymphoblastic leukemia: a TACL pilot study","volume":"26","author":"Burke","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.bneo.2026.100247_bib34","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/pbc.22456","article-title":"Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the Therapeutic Advances in Childhood Leukemia (TACL) consortium","volume":"55","author":"Messinger","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.bneo.2026.100247_bib35","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28062","article-title":"Treatment of children with relapsed and refractory acute lymphoblastic leukemia with mitoxantrone, vincristine, pegaspargase, dexamethasone, and bortezomib","volume":"67","author":"August","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.bneo.2026.100247_bib36","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28115","article-title":"Bortezomib-based four-drug induction does induce a response in advanced relapsed ALL but cure remains elusive","volume":"67","author":"Messinger","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"10.1016\/j.bneo.2026.100247_bib37","first-page":"218","article-title":"Post-marketing analysis of peripheral neuropathy burden with new-generation proteasome inhibitors using the FDA adverse event reporting system","volume":"38","author":"Mina","year":"2021","journal-title":"Turk J Haematol"},{"issue":"9","key":"10.1016\/j.bneo.2026.100247_bib38","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/ajh.23778","article-title":"A therapeutic trial of decitabine and vorinostat in combination with chemotherapy for relapsed\/refractory acute lymphoblastic leukemia","volume":"89","author":"Burke","year":"2014","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.bneo.2026.100247_bib39","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/SPC.0000000000000266","article-title":"Proteasome inhibitor-induced gastrointestinal toxicity","volume":"11","author":"Stansborough","year":"2017","journal-title":"Curr Opin Support Palliat Care"},{"issue":"7","key":"10.1016\/j.bneo.2026.100247_bib40","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1007\/s00432-024-05716-3","article-title":"Gastrointestinal toxicities of proteasome inhibitor therapy","volume":"150","author":"Shah","year":"2024","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000580?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328026000580?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:17:14Z","timestamp":1790687834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328026000580"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2950328026000580"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100247","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ixazomib with chemotherapy for childhood relapsed acute lymphoblastic leukemia: a TACL consortium report","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2026.100247","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Society of Hematology. Published by Elsevier Inc. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100247"}}